Back to search

University of Crete (UOC)

Detection and comparison of Circulating Tumor Cells and circulating free DNA at patients with stage III colorectal cancer receiving three or six months of adjuvant chemotherapy

Abstract

dc:description

Colorectal cancer (CRC) remains a major global health concern, with significant implications for patient outcomes and healthcare systems. Among patients diagnosed with stage III disease, approximately 30% will experience recurrence despite receiving standard treatment. Surgery is a critical component of the curative approach; however, adjuvant chemotherapy plays a pivotal role in reducing recurrence risk and improving overall survival. Historically, the FOLFOX regimen, consisting of 5-Fluorouracil, Leucovorin, and Oxaliplatin administered over six months, was considered the gold standard. However, the IDEA trial (2018) introduced a paradigm shift by demonstrating that a three-month adjuvant regimen, particularly with Capecitabine-Oxaliplatin (CAPOX), could achieve comparable outcomes in patients with lower TNM stage disease. This adjustment in treatment duration was particularly beneficial for patients experiencing adverse effects, particularly neurotoxicity, which can significantly impact quality of life and even impair the ability to perform daily activities or work-related tasks. Given the evolving landscape of adjuvant therapy, the identification of reliable biomarkers to optimize treatment strategies has become an area of intense research. This study aimed to assess the prognostic and predictive value of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) detection in this treatment setting, potentially aiding in therapy optimization and individualized patient management. Additionally, it sought to provide laboratory-based validation of the IDEA trial findings and to compare two distinct methods for CTC detection. A prospective, non-randomized, single-center trial was conducted, enrolling 175 patients with stage III CRC undergoing adjuvant chemotherapy. Patients were treated with either CAPOX or FOLFOX for a duration of three or six months, depending on physician and patient preference. Peripheral blood samples were collected at three critical time points: prior to treatment initiation (baseline), after three months of treatment, and at six months (for patients completing the longer regimen). CTCs detection was performed using two methodologies: triple immunofluorescence assay testing (IFAT) and real-time quantitative polymerase chain reaction (RT-qPCR). Simultaneously, ctDNA analysis was conducted via next-generation sequencing (NGS) to explore its potential role as a prognostic biomarker. This study investigated the dynamics of CTCs and ctDNA as indicators of treatment response, recurrence risk, and overall prognosis. Among the 175 participants, 58.9% were male, and the median age was 65 years. All patients had a performance status of 0-1, with 69.1% presenting with left-sided tumors. Treatment allocation was as follows: 38.3% received three months of therapy, while 49.7% were treated with FOLFOX. The median disease-free survival (DFS) and overall survival (OS) were 17.2 and 31.2 months, respectively. CTCs were detected in 45.5%, 40.7%, and 50.8% of patients at baseline, three months, and six months, respectively, using IFAT. When assessed using RT-qPCR, detectable CTCs were present in 39.9% of patients at baseline, 32.4% at three months, and 51.6% at six months. A statistically significant reduction in CTC levels was observed after three months in patients treated with CAPOX (p=0.025), reinforcing the effectiveness of the shortened regimen. However, a notable increase in CTCs between three and six months was observed in patients with right-sided tumors (p=0.022) and those younger than 70 years old (p=0.053). The presence of CTCs detected via IFAT at baseline was significantly associated with poorer DFS (p=0.02), highlighting their potential role as prognostic markers. Among the subset of patients tested for ctDNA (n=77, baseline only), all exhibited at least one detectable mutation. The most frequently identified mutations included AXIN2, BIRC5, DCC, APC2, and PIK3R2. Further analysis revealed that the presence of LEF1 and MAPK1 mutations was significantly associated with decreased DFS (p=0.007 and p=0.032, respectively), while AXIN mutations correlated with reduced OS (p=0.039). These findings underscore the potential of ctDNA as a valuable prognostic biomarker for risk stratification and treatment personalization. At the last follow-up, conducted five years after the enrollment of the first patient, 81.1% of the study participants were still alive, further supporting the efficacy of adjuvant therapy in improving long-term outcomes for stage III CRC patients. The results of this study reinforce the efficacy of a three-month adjuvant regimen, particularly with CAPOX, demonstrating significant reductions in CTC levels. The persistence of detectable CTCs following six months of FOLFOX therapy suggests potential treatment resistance and the presence of micrometastatic disease, underscoring the need for tailored therapeutic strategies. Both techniques used for CTC detection in this study—IFAT and RT-qPCR—appeared equally effective, suggesting that either could be employed in clinical settings based on availability and technical feasibility. Additionally, the prognostic significance of specific ctDNA mutations highlights its potential role in guiding treatment decisions. The integration of CTC and ctDNA analysis into routine clinical practice could enable better risk stratification, allowing for more personalized adjuvant therapy regimens. Further large-scale, multicenter trials are necessary to validate these findings and establish standardized protocols for incorporating these biomarkers into routine patient care. Ultimately, such advancements in biomarker-driven treatment approaches could significantly enhance patient outcomes, reducing recurrence rates and improving long-term survival in CRC patients.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koulouridi, Asimina
  • Κουλουρίδη, Ασημίνα

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58660

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koulouridi, Asimina; Κουλουρίδη, Ασημίνα. Detection and comparison of Circulating Tumor Cells and circulating free DNA at patients with stage III colorectal cancer receiving three or six months of adjuvant chemotherapy. University of Crete (UOC), 2025. http://hdl.handle.net/10442/hedi/58660